摘要
目的了解文拉法辛缓释剂与丁螺环酮治疗广泛性焦虑障碍的疗效和安全性。方法将符合入组标准的患者随机分为研究组和对照组,研究组口服文拉法辛缓释剂,对照组口服丁螺环酮,疗程4周。临床疗效判定依据汉密尔顿焦虑量表(HAMA)减分率,不良反应采用不良反应量表(TESS)评定。结果研究组有效率为78.38%,对照组有效率为74.36%,两组有效率比较,差异无统计学意义(χ2=0.17,P>0.05)。但在第2周时研究组抗焦虑效果优于对照组,两组不良反应比较,差异无统计学意义。结论文拉法辛缓释剂与丁螺环酮治疗广泛性焦虑症均有较好的疗效,不良反应少,但文拉法辛缓释剂抗焦虑效果在治疗第2周时优于丁螺环酮。
Objective To explore the efficacy and safety of venlafaxine sustained release preparation and buspirone in the treatment of generalized anxiety disorder（GAD）.Methods The patients accorded with the inclusion criteria were randomly divided into the study group and the control group.The study group was administered with venlafaxine sustained release preparation and the control group was treated with buspirone for 4 weeks.The clinical efficacy was evaluated using the reducing score rate of Hamilton Anxiety Scale（HAMA）,and adverse reactions was assessed using the Treatment Emergent Symptom Scale（TESS）.Results The effective rate was 78.38% and 74.36% in the study group and the control group respetively,without statistical difference between the two groups（χ2=0.17,P0.05）.While at the second week,the anxiolytic effect in the study group was better than that in the control group.No statistical difference in adverse reactions existed between the two groups.Conclusion Venlafaxine sustained release preparation and buspirone have better efficacy in the treatment of GAD with less adverse reactions.But at the second week,the anxiolytic effect in venlafaxine sustained release preparation is superior to buspirone.
出处
《现代医药卫生》
2012年第12期1781-1782,共2页
Journal of Modern Medicine & Health
关键词
焦虑症
迟效制剂
文拉法辛
丁螺环酮
病例对照研究
Anxiety disorders
Delayed-action preparations
Veniafaxine
Buspirone
Case-control studies
